Abstract
The present studies investigated whether SDZ 220-581 ((S)-alpha-amino 2'chloro-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoic acid), a potent, competitive antagonist at the NMDA glutamate receptor subtype, reversed haloperidol-induced catalepsy in rats, a widely used model of Parkinson's disease. SDZ 220-581 (0.32-3.2 mg/kg i.p.) dose- and time-dependently reduced the time spent in an abnormal position induced by haloperidol (1.0 mg/kg s.c.). Compared to other NMDA receptor antagonists the rank order of potency was MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine) > SDZ 220-581 > SDZ EAA 494 (D-CPPene: (S)-(E)-4-(3-phosphonoprop-2-enyl)-piperazine-2-carboxylic acid) > SDZ EAB 515 ((S)-alpha-amino-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoic acid). Since it has been demonstrate that SDZ 220-581 counters the effects of L-dihydroxyphenylalanine (L-DOPA) on the motor disturbances of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-pre-treated primates, the results suggest that the reversal of haloperidol-induced catalepsy by competitive NMDA receptor antagonists may not be predictive of efficacy in other models of Parkinson's disease.
References
Jan 1, 1992·Journal of Neural Transmission. General Section·A SvenssonM L Carlsson
Jul 1, 1992·Annals of Neurology·N M RupniakC D Marsden
Jan 1, 1991·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·P A LöschmannC D Marsden
Jul 17, 1990·European Journal of Pharmacology·M Morelli, G Di Chiara
Jan 1, 1990·Psychopharmacology·S P CloseA S Marriott
Jan 1, 1990·Life Sciences·A K Mehta, M K Ticku
Aug 1, 1989·Trends in Neurosciences·T Klockgether, L Turski
Mar 1, 1989·Pharmacology, Biochemistry, and Behavior·W J Schmidt, M Bubser
Sep 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·E H WongL L Iversen
Jan 1, 1982·The Kurume Medical Journal·Y IdaN Nagasaki
Dec 1, 1994·Neurochemistry International·D A LoweT G White
Jan 1, 1993·Journal of Neural Transmission. General Section·J T Greenamyre
Jun 11, 1993·European Journal of Pharmacology·N A MooreJ D Leander
Mar 2, 1993·European Journal of Pharmacology·S M PapaT N Chase
Jun 1, 1996·Neuropharmacology·S UrwylerW Müller
Jun 1, 1991·Amino Acids·W J SchmidtW Hauber
Citations
Apr 8, 1999·Neuropharmacology·M Karcz-KubichaW Danysz
Apr 15, 2000·Pharmacology, Biochemistry, and Behavior·T M Ballard, K H Mcallister
Nov 9, 2007·Behavioural Pharmacology·Katherine L NicholsonRobert L Balster
Apr 5, 2013·PloS One·Ovidiu D IancuRobert Hitzemann
Jul 23, 2020·G3 : Genes - Genomes - Genetics·Paola Giusti-RodríguezFei Zou
Apr 17, 2003·Drugs & Aging·Michael J MarinoP Jeffrey Conn
Apr 6, 2021·The European Journal of Neuroscience·Isabelle WakuAmanda R de Oliveira